These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

992 related items for PubMed ID: 18843272

  • 1. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED, Lamb DJ, Khera M, Murthy L, Lipshultz LI.
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [Abstract] [Full Text] [Related]

  • 2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM, Simhan J, Carson CC.
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [Abstract] [Full Text] [Related]

  • 3. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL, Morgentaler A.
    Int J Impot Res; 2006 May; 18(2):201-5. PubMed ID: 16177827
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI.
    Int J Impot Res; 2008 May; 20(2):213-7. PubMed ID: 17898800
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
    Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD.
    J Androl; 2002 May; 23(6):922-6. PubMed ID: 12399540
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy.
    Gould DC, Feneley MR, Kirby RS.
    BJU Int; 2006 Jul; 98(1):1-4. PubMed ID: 16831134
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G.
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [Abstract] [Full Text] [Related]

  • 14. Testosterone replacement therapy after primary treatment for prostate cancer.
    Agarwal PK, Oefelein MG.
    J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Testosterone concentrations in hair of hypogonadal men with and without testosterone replacement therapy.
    Thomson S, Koren G, Van Steen V, Rieder M, Van Uum SH.
    Ther Drug Monit; 2009 Dec; 31(6):779-82. PubMed ID: 19809386
    [Abstract] [Full Text] [Related]

  • 19. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
    Morote J, Ramirez C, Gómez E, Planas J, Raventós CX, de Torres IM, Catalán R.
    BJU Int; 2009 Aug; 104(4):486-9. PubMed ID: 19220251
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.